New AIM admission: Pri0r1ty Intelligence has much to prove

Formerly standard listed shell Alteration Earth did not make an acquisition large enough to retain a full listing and switched to AIM. The shell purchased Pri0r1ty AI, which has developed a platform to automate processes to help smaller businesses to grow. The name was changed to Pri0r1ty Intelligence.

There is already an article on the UK Investor Magazine website that covers the technology Pri0r1ty AI bolsters the UK's small cap artificial intelligence sector but lags behind peers in terms of innovation - UK Investor Magazine.

In the four months to October 2024, revenues were £14,000,...

Aquis weekly movers: Global Connectivity invests in decommissioning copper cables

Global Connectivity (LON: GCON) is investing £50,000 in PLUG Group, which is a 4% stake. PLUG is developing opportunities to extract decommissioned copper cables for South American telecoms companies. Livia Meyer has returned 32.5 million shares and paid £50,000 for the other five million shares subscribed for. Executive chairman Dr Keith Harris has paid the £200,000 he owes for shares he acquired. Barry Hersh has still not paid the £375,000 for the 37.5 million shares that he subscribed for. The share price improved 31.8% to 0.725p.

Blue Sky Vision has exercised its option to subscribe for 20 million shares in Valereum (LON: VLRM) at 10p each. The share price increased 22.2% to 27.5p.

Tap Global Group (LON: TAP) has been granted virtual asset service provider registration in Bulgaria. This is a step towards expanding in the EU. The share price moved ahead by 20.8% to 2.9p.

Three directors of Invinity Energy Systems (LON: IES) bought shares at 14.85p/share. Chairman Neil O’Brien bought 135,000 shares, chief executive Jonathan Marren acquired 134,680 shares and finance director Adam Howard purchased 134,333 shares. The share price rose 20.3% to 17.75p.

SulNOx Group (LON: SNOX) reported a rise in interim revenues from £136,000 to £440,000. The loss increased from £870,000 to £1.17m. There was £804,000 in the bank at the end of September 2024. The share price improved 8.7% to 75p.

FALLERS

Coinsilium (LON: COIN) has entered into a strategic collaboration with Otomato Inc, a Web3 technology platform for autonomous agent-based solutions. The idea is to maximise the value of Coinsilium’s digital assets. The initial term is 12 months. The share price dipped 5.26% to 3.6p.

KRI (LON: KR1) had net assets of 100.04p/share at the end of November 2024. Income of £771,347 was generated during the month. There is cash of £624,000. The share price slid 0.74% to 67.5p.

AIM weekly movers: Fusion Antibodies chart indicates rise and potential Poolbeg Pharma merger sparks share price drop

0

Jonathan Rowland increased his stake in fire suppression technology company Zenova Group (LON: ZED) to 7.8%. The share price rebounded 45.5% to 0.8p.

Clinical antibodies supplier Fusion Antibodies (LON: FAB) was highlighted by Zak Myr on his Bulletin Board Heroes broadcast on Thursday. According to his assessment of the chart he was targeting 9.25p by the end of January. He said that the next major resistance point is 10p. There were 3.1 million shares traded on Thursday and on Friday. The share price was 45% higher at 10.15p, which suggests that there could be further improvement.

Trading in Gfinity (LON: GFIN) shares was suspended on 2 January because accounts for the year to June 2024 have been delayed and were not be published by the end of 2024. Gfinity achieved monthly profitability in November. The share price increased 36.4% to 0.075p.

Revolution Beauty (LON: REVB) has come to a confidential agreement with Chrysalis Investments (LON: CHRY) over the claims related to its investment in the company when it joined AIM in July 2021. Last year, Chrysalis Investments issued draft particulars of a claim £39m plus additional consequential loss of £6.2m. Chrysalis Investments will be paid a non-material amount of cash with out admission of liability. This removes a hangover on the Revolution Beauty share price, which recovered 36.3% to 19.76p.

Tungsten West (LON: TUN) had £40,000 in cash at the end of September 2024. There is a provisional agreement to place a further £2.8m of loan notes. Progress is being made towards the reopening of the Hemerdon tungsten and tin mine in Devon. The share price rose 24.2% to 4.1p.

FALLERS

Poolbeg Pharma (LON: POLB) is in talks with potential bidder HOOKIPA Pharma (NASDAQ: HOOK) about an all-share offer from the Nasdaq-listed company. The indicated proposal is 0.03 of a HOOKIPA share for each Poolbeg share. Cancer and infectious disease treatments developer HOOKIPA intends to raise up to $30m. That will fund phase 2a trails for POLB 001 and trials of two other treatments. HOOKIPA shareholders would receive a contingent value right instrument entitling them to 55% of milestone payments made by Gilead for HB-400 and HB-500 programmes. This could be worth up to $407.5m. They are also entitled to 80% of the proceeds generated by the HB-200 programme. The Poolbeg Pharma share price dived 41.7% to 4.2p.

Trading in ADM Energy (LON: ADME) shares was restored following the publication of 2023 accounts and interims for 2024. In 2023, there was a £16.8m impairment charge. There was £66,000 in cash at the end of June 2024 and two investments have generated cash, but ADM Energy is still constrained by a lack of cash. The share price slumped 41.2% to 0.25p.

Pri0r1ty Intelligence Group (LON: PR1) joined AIM on 30  December following the reversal of the AI customer relationship technology company into Alteration Earth. The business provides AI tools to automate areas such as social media and governance for smaller companies. Spreadex has sold a 3.99% stake and retains voting rights through financial instruments of 0.75%. The share price declined by 24.1% from the placing price to 10.25p, although it is 18% down on the Alteration Earth suspension price of 12.5p.  

Spreadex Ltd has cut its shareholding, via voting rights through financial instruments, in Tiger Royalties and Investments (LON: TIR) from 4.94% to 3.53%. The company is in the process of acquiring a technology incubator business. The share price slipped 22.2% to 0.175p.

Security technology developer Thruvision (LON: THRU) has appointed Victoria Balchin as chief executive. She was appointed finance director in October 2022 and she is retaining the role. Tom Black will continue as executive chairman and focus on sales. The share price declined 18.7% to 6.5p.

Tullow Oil wins tax case

1

Tullow Oil (LON: TLW) is the best performing share in the FTSE Small Cap index today, following the announcement late on Thursday that there was a successful outcome to the Ghana tax arbitration. The share price recovered 12.3% to 24.55p.

The International Chamber of Commerce (ICC) tribunal related to the application of Branch Profit Remittance tax to the oil and gas company’s Deepwater Tano and West Cape Three Points petroleum agreements, offshore Ghana. The tribunal decided that the tax is not applicable to the Tullow Oil assets in Ghana.

This means that Tullow Ghana does not have to pay the $320m tax assessment and there will be no future exposure to the tax for the specific agreements.

Two further disputed tax claims were referred to the ICC two years ago. In the interim accounts, Tullow Oil said that it had more than $1bn of disputed tax claims in Ghana and other countries.

Before Christmas, Kosmos Energy, which also has interests in Ghana, decided against a bid for Tullow Oil. The share price is still more than one-third lower than one year ago.  

AIM movers: Volex acquisition beats target and Revolution Beauty continues recovery

0

Revolution Beauty (LON: REVB) shares continue to recover following the confidential agreement with Chrysalis Investments (LON: CHRY) over its legal claim relating to the accuracy of the flotation prospectus in 2021. It rebounded a further 10.4% to 19.61p.

Stonehage Fleming has cut its shareholding in retailer Quiz (LON: QUIZ) from 13% to 3.86% and Amraj Gill continues to buy with that stake rising to 11.1%. This dealing is ahead of a planned departure from AIM, if shareholders agree at the general meeting. The share price improved 4.65% to 0.9p.

Encompass Capital Advisors reduced its stake in PetroTal Corp (LON: PTAL) from 3.71% to 2.93%. This follows a reduction from around 6% during November. The share price is up 3.1% to 33.25p.

The estate of William Black has reduced its stake in Surface Transforms (LON: SCE) from 5.62% to 4.76%. The stake was increased from 4.95% when the share price was around its low. It has nearly doubled since then and has risen a further 3.03% to 0.51p.

Power and transmission products supplier Volex (LON: VLX) says Turkey-based acquisition Murat Ticaret has exceeded its profit targets for the first 12 months since its purchase. The deferred consideration payment is €10m in cash and 2.88 million Volex shares. The share price increased 0.46% to 274.75p.

FALLERS

Cancer treatments developer Hutchmed (China) Ltd (LON: HCM) has lost some of yesterday’s gains following the sale of its non-core 45% interest in Shanghai Hutchison Pharmaceuticals for $608m and the acceptance of a new drug application in China for savolitinib in combination with AstraZeneca’s Tagrisso as a treatment for lung cancer. The share price fell 1.21% to 244p.

Richard Griffiths has had his stake in Seeing Machines (LON: SEE) diluted to less than 3%. The share price is 1.13% lower at 4.5975p.

Share Tip: Against a background of bumper cinema slates and ahead of its Trading Update, the shares of the Everyman Media Group, now 52.50p with a TP 180p, could look right for a quick run upwards 

It has been stated that the core objective of the cinema industry has remained unchanged for almost a century – which is basically to provide audiences with a consistently excellent ‘big screen’ experience. 

The cinema business has had to constantly reinvent itself to ensure it has continued to offer the best possible experience to customers at an affordable price.  

In addition to bringing a diverse range of content to screens, cinemas have to consider their food and drink, and other hospitality offers, as well as the comfort of their cinemas, ticket prices and promotion...

AIM movers: Revolution Beauty settlement and potential Nasdaq merger for Poolbeg Pharma

1

Revolution Beauty (LON: REVB) has come to a confidential agreement with Chrysalis Investments (LON: CHRY) over the claims related to its investment in the company when it joined AIM in July 2021. Last year, Chrysalis Investments issued draft particulars of a claim £39m plus additional consequential loss of £6.2m. Chrysalis Investments will be paid a non-material amount of cash with out admission of liability. This removes a hangover on the Revolution Beauty and the share price rebounded 28.4% to 17.65p.  

Emmerson (LON: EML) has secured up to $11m of litigation and working capital funding. Boies Schiller Flexner, which has a strong track record, is litigation counsel for the legal dispute with the Government of Morocco over the permitting of the Khemisset potash project. The post-tax NPV8 of the project is $2.2bn. The share price recovered 27.1% to 0.775p.

Marketing services provider The Mission Group (LON: TMG) has completed its restructuring with the sale of AprilSix to US-based Marketbridge for up to £17.4m. The initial payment is £10.5m and reduces pro forma net debt to £17m. This will enable the company to negotiate an extension to its debt agreement. AprilSix generated 13.5% of 2023 revenues of £86.3m. A share buyback of up to £1.5m will be launched. There could be a dividend paid for 2025. The share price increased 16.7% to 28p.

Griffin Mining (LON: GFM) has recommenced mining at the Caijiaying mine on 30 December following an accident last year. The share price rose 7.88% to 157.5p.

Cancer treatments developer Hutchmed (China) Ltd (LON: HCM) has followed up the sale of its non-core 45% interest in Shanghai Hutchison Pharmaceuticals for $608m with news of the acceptance of a new drug application in China for savolitinib in combination with AstraZeneca’s Tagrisso as a treatment for lung cancer. The Chinese authorities could make a decision on the application within 18 months. There could be a market worth around $1bn in China. The share price improved 4.04% to 244.5p.

FALLERS

Poolbeg Pharma (LON: POLB) is in talks with potential bidder HOOKIPA Pharma (NASDAQ: HOOK) about an all-share offer from the Nasdaq-listed company. The indicated proposal is 0.03 of a HOOKIPA share for each Poolbeg share. Cancer and infectious disease treatments developer HOOKIPA intends to raise up to $30m. That will fund phase 2a trails for POLB 001 and trials of two other treatments. HOOKIPA shareholders would receive a contingent value right instrument entitling them to 55% of milestone payments made by Gilead for HB-400 and HB-500 programmes. This could be worth up to $407.5m. They are also entitled to 80% of the proceeds generated by the HB-200 programme. The Poolbeg Pharma share price slumped 35.9% to 4.55p, which is near to an all-time low.

Non-executive director John Stafford stepped down from the Nostra Terra Oil & Gas (LON: NTOG) board. The share price slipped 8.33% to 0.0275p.

Tungsten West (LON: TUN) had £40,000 in cash at the end of September 2024. There is a provisional agreement to place a further £2.8m of loan notes. Progress is being made towards the reopening of the Hemerdon tungsten and tin mine in Devon. The share price declined 6.67% to 3.5p.

Ex-dividends

FIH Group (LON: FIH) is paying an interim dividend of 1.25p/share and the share price rose 8p to 265p.

Jet2 (LON: JET2) is paying an interim dividend of 4.4p/share and the share price dipped 32p to 1551p.

James Latham (LON: LTHM) is paying an interim dividend of 7.95p/share and the share price increased 10p to 1155p.

Building a Weekly Trading Routine Around Your Forex Calendar

Trading in the foreign exchange market requires more than just technical analysis and chart patterns. A well-structured routine built around a forex calendar can mean the difference between consistent profits and costly mistakes. By organising your trading week around key economic events, you can make more informed decisions and better manage your risk exposure.

The Foundation: Understanding Your FX Calendar

Your FX calendar is more than just a schedule of economic releases – it’s a strategic tool that helps you anticipate market movements. Each week brings a new set of economic indicators, central bank announcements, and geopolitical events that can impact currency pairs. Understanding how to interpret and utilize this information is crucial for developing effective trading strategies.

Creating Your Weekly Framework

Sunday Evening: Planning and Preparation

Start your trading week before the markets open. Sunday evening is ideal for:

  • Reviewing the upcoming week’s major economic events
  • Identifying potential high-impact news releases
  • Setting preliminary price alerts for key levels
  • Updating your forex bot parameters if you use automated trading
  • Checking for any significant gap openings in the Asian session

Monday to Wednesday: Building Momentum

These days typically see steady market activity, making them ideal for implementing your core strategies:

  • Execute trades based on your pre-planned setups
  • Monitor medium-impact economic releases
  • Focus on major currency pairs during peak liquidity hours
  • Adjust positions based on emerging market trends
  • Maintain strict risk management protocols

Thursday: High-Impact Day

Thursday often brings significant market movements due to important economic releases:

  • Pay special attention to US employment data and central bank announcements
  • Be prepared to adjust or close positions before major news events
  • Look for potential breakout opportunities
  • Review and update your stop-loss levels
  • Consider reducing position sizes during volatile periods

Friday: Consolidation and Analysis

The last trading day of the week requires a more conservative approach:

  • Close or reduce high-risk positions before the weekend
  • Document the week’s trading performance
  • Analyze what worked and what didn’t
  • Update your trading journal
  • Begin preliminary analysis for the following week

Essential Components of Your Daily Routine

Pre-Market Analysis (30 Minutes)

Before each trading session:

  1. Check overnight developments
  2. Review your forex calendar for upcoming events
  3. Identify key support and resistance levels
  4. Assess overall market sentiment
  5. Update your watchlist

Active Trading Sessions (2-4 Hours)

During your chosen trading windows:

  1. Monitor open positions
  2. Execute planned trades
  3. Maintain position sizing discipline
  4. Follow your risk management rules
  5. Document trade rationale and outcomes

Post-Session Review (30 Minutes)

After completing your trading day:

  1. Calculate daily performance metrics
  2. Update your trading journal
  3. Identify areas for improvement
  4. Prepare for the next session
  5. Adjust strategies as needed

Leveraging Technology Effectively

While many traders rely on manual analysis, incorporating technology can enhance your routine. A well-configured forex bot can help monitor markets 24/7 and execute trades based on your predetermined criteria. However, remember that automation should complement, not replace, your human judgment.

Risk Management: The Cornerstone of Success

No trading routine is complete without robust risk management protocols. Successful traders typically:

  • Limit risk to 1-2% per trade
  • Use appropriate position sizing
  • Set clear stop-loss and take-profit levels
  • Avoid trading during major news events if their strategy isn’t designed for it
  • Maintain a healthy work-life balance to prevent emotional trading

Adapting Your Routine for Profitable Outcomes

A trading routine isn’t static – it should evolve with your experience and changing market conditions. Regular review and adjustment of your approach helps ensure sustained performance. Pay attention to:

  • Which times of day yield your best results
  • Which currency pairs suit your trading style
  • How different market conditions affect your strategy
  • Your emotional state during trading sessions
  • The effectiveness of your risk management approach

Measuring Success

Track your progress using both quantitative and qualitative metrics:

  • Win rate and risk-reward ratio
  • Monthly and quarterly returns
  • Adherence to your trading plan
  • Emotional control during trades
  • Quality of trade execution

Conclusion

Building a successful trading routine around your forex calendar takes time and dedication. The key is consistency in execution and continuous improvement. By following a structured approach, maintaining discipline in risk management, and regularly reviewing your performance, you can work toward achieving consistent profits in the forex market.

Remember that profitable trading isn’t about making money every day – it’s about following your routine and trusting your process. The most successful traders are those who stick to their plans and maintain discipline, especially during challenging market conditions.

Your trading routine should serve as a framework for success, not a rigid set of rules that prevent adaptation to changing market conditions. Stay flexible, keep learning, and always prioritize risk management over potential profits. With time and dedication, your routine will become second nature, helping you navigate the complex world of forex trading with greater confidence and consistency.

Share Tip: Synectics – there is a good chance that this group’s products are watching you, now you should watch its shares, looking for a 50% uplift 

It has its eye on you - it knows what you are doing, where you are going – whether in a train, on the street, in a casino – or just about anywhere. 

Synectics (LON:SNX) is a leader in advanced security and surveillance systems that help protect people, property, communities, and assets around the world.  

The meaning of the word synectics is a problem-solving methodology that stimulates thought processes which the subject may be unaware. 

The word comes from the Greek, for the joining together of different and apparently irrelevant elements. 

However, for this ...

Pri0r1ty AI bolsters the UK’s small cap artificial intelligence sector but lags behind peers in terms of innovation

Pri0r1ty Intelligence Group listed on London’s AIM this week, bolstering the UK’s artificial intelligence small-cap sector by adding to the selection of growth companies with AI at the heart of their operations.

The UK’s AI sector is, at long last, starting to build momentum with more and more companies developing AI services and offering public equity investors exposure to the sector, which will likely drive economic growth in the years to come.

However, investors should consider whether London’s latest addition enriches the sector in terms of innovation. A study of Pri0r1ty’s admission document suggests their platform isn’t as groundbreaking as it first looks with much of their offering a replication of tools available elsewhere.

The UK Investor Magazine has previously highlighted technology and marketing companies that jump on the latest trends and raise funds to develop products but struggle to build meaningful market traction. For example, in 2020, we explored the fundamental constraints of Bidstack’s in-gaming native advertising model and the warning signs of slow revenue growth, which can be read here. In this article, we take a similar approach to Pri0r1ty Intelligence Group.

Although PriOr1ty’s IPO – facilitated by a reverse takeover (RTO) of a SPAC – is a major positive for London’s small-cap tech sector, the company’s service doesn’t appear to offer anything particularly new to a target market that already has many existing options to choose from. And the pricing strategy outlined in the admission document suggests their service may be far more expensive.

The admission document names Hootsuite, Jasper AI and Seedlegals as competitors. In reality, the competition probably runs into the hundreds of companies.

In social management alone, there are already dozens of established services with a core of around 10 services that any social media manager worth their salt will know intimately. Many of these cost no more than £15 per month. Hootsuite, the market leader, charges £89 per month for its ‘professional’ package. This compares to £499 for PriOr1ty’s package.

PriOr1ty launched the ‘Pri0r1ty Advisor GPT’ chatbot-style customer service tool called ‘Pri0r1ty Spotlight’ powered and trained by AI LLMs in late 2024. This has been one of the most exciting areas of Gen AI so far, as it reduces the need for customer service staff and is one of the most straightforward ways of implementing AI to cut costs.

However, PriOr1ty faces the challenge of competing against the heavyweight CRM companies HubSpot, Zoho, and Salesforce, as well as billion-dollar Intercom – a leader in AI Agent customer service – all of whom have invested tens of millions in integrating similar AI-powered functions into their offerings.

In terms of pricing, Hubspot costs around £50 per user per month, while Intercom starts at $29 per month.

It is also worth noting that, at the time of writing, PriOr1ty’s case study AI chatbot developed for a drinks company called Favela Cerveja featured on PriOr1ty AI’s website homepage isn’t immediately available on Favela Cerveja’s own website to test out.

PriOr1ty has earmarked five different platforms/services to be launched in 2025. It is not clear whether these will be standalone services or accessible on one platform. It is clear, however, that each service by itself isn’t particularly groundbreaking.

‘PriOr1ty Ventures’, as detailed in the admission document, doesn’t seem to offer anything already accessible through other long-established services. Google Analytics, ChatGPT and a simple CRM like Hubspot will be able to cover all of the key features. These are all systems marketers will likely have in place already.

The company’s success will hinge on price and user experience. PriOr1ty will rightly have some success onboarding organisations with limited existing marketing operations or inexperienced marketing staff.

However, it’s difficult to pinpoint why firms with established marketing or public relations functions would migrate over their existing work streams to PriOr1ty‘s service, which could result in higher costs, depending on the size of the organisation. This should be a consideration for investors.

Organisations of any substantial size require deeply specific tools to meet the demands of sometimes complex workstreams. It’s inconceivable for a company with departments for finance, marketing, sales, research, and legal, each with its own dedicated team, will find the depth it needs in Pri0r1ty’s services and products.

Most of PriOr1ty’s ‘product key functionalities’ outlined in the admission document can be completed very easily using AI tools like Jasper AI, ChatGPT, Claude or Gemini alongside traditional applications like the Adobe suite.

For more than a year, marketing teams around the world have been using AI tools as a matter of course to complete day-to-day tasks like creating content slated as ‘key functionalities’ of ‘Pri0r1ty Spotlight’.

Tasks mentioned by Pri0r1ty as core to their product, such as ‘Build content based on stakeholder feedback’ or ‘Generate press releases, regulatory news or internal memos’ can be done in seconds using LLM tools like ChatGPT, Jasper AI or Claude, should someone wish to substitute a human for AI in the creation of crucial communications. The suggestion that Pri0r1ty’s users will generate important regulatory news using relatively new and untested AI is interesting.

Overall, it appears Pri0r1ty will act more like a marketing agency bringing together a suite of services for SME marketing companies with little internal marketing capabilities. It doesn’t appear to offer anything that will win over the mass market.

Valuation

This questions the valuation and whether the current market cap can be sustained. For the sake of confidence in London’s small-cap markets, one would hope sales would rise sharply to justify the rich valuation.

We recently highlighted GenIP as the standout UK small-cap Gen AI stock. This remains the case after PriOr1ty‘s AIM admission. GenIP has identified a clear pain point for its target market and is providing a solution to a problem that is being adopted by some of the world’s largest technology firms. This type of traction is absent from PriOr1ty‘s admission document. 

There are also a number of companies pivoting towards AI with much lower valuations despite being at a similar stage to PriOr1ty. Cel AI is a notable example.